BETA Beta Drugs Q4 FY25 results (Jan–Mar 2025) and concall
Beta Drugs Limited reported strong financial performance for FY25, with consolidated revenue growing 22.5% to ₹362.35 crores and net profit increasing 25.8% to ₹45.83 crores. The exports segment was a key growth driver, surging 73%. The company is actively expanding its product pipeline, pursuing regulated market approvals, and expects its Cosmetology division to turn profitable soon, despite some production disruptions due to an audit and delays in Mainboard migration.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 48 | 54 |
| EBITDA | 6 | 5 |
| Net profit | 1 | 1 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
